logo-loader
RNS
Cello Health PLC

Cello Health PLC - Directorate Change

RNS Number : 0671H
Cello Health PLC
12 November 2018
 

12 November 2018

 

Cello Health plc

("Cello", the "Company", or the "Group")

 

Directorate Change

 

Cello Health plc (AIM: CLL), the global healthcare focused advisory group, is pleased to announce the appointment of Michele Luzi as Non-Executive Director with immediate effect.

 

Michele is an Advisory Partner of Bain and Company, the global management consultancy, and has served on its global Board. He joined Bain in 1990 and is now reducing his time commitment to the partnership. Since 2010 Michele has served on the Board of Midatech Pharma PLC, a UK Nanotechnology Biotech PLC. Michele is an Italian national.

 

Mark Scott, Chief Executive, commented: "We are delighted to have Michele on board. He brings with him first-hand experience of growing a global professional service business, as well as a wide knowledge of the healthcare sector. His contribution will be very helpful as we seek to expand Cello's global footprint."

 

 

Enquiries:

 

Cello Group

020 7812 8460

Mark Scott, Chief Executive


Mark Bentley, Finance Director




Cenkos Securities

0207 397 8900

Mark Connelly

Harry Hargreaves


 

Appendix

Full name (age)

Michele Luzi (61)

Current directorships / partnerships:

ASHWICK DEVELOPMENTS LIMITED

ASHWICK PROJECTS LIMITED

BAINCOMPANY PARTNERS, L.P.

JUBILEE FILM PARTNERSHIP LLP

MIDATECH PHARMA PLC

PROJECT 99 LIMITED

ST JAMES MEDIA LLP

VIESVI LIMITED

Previous directorships / partnerships (in the last five years):

MIDATECH LTD

RMD TRAFFORD HOUSE 2000 LIMITED

RMD TRAFFORD HOUSE LLP

YELLOW SKY PUBLISHING LIMITED

 

As at today's date, Mr Luzi does not hold any ordinary shares in the capital of the Company.

There are no further disclosures to be made pursuant to Schedule 2(g) of the AIM Rules for Companies in respect of Mr Luzi's appointment.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOALLFLLLLLFLIT
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read